oMeds
All answers
Answer · metabolic

Early insulin resistance on labs — what is the first oMeds step?

Short answer

Insulin resistance is routed by severity and BMI. Lifestyle and metabolic support first; GLP-1 pathways (semaglutide or tirzepatide) for eligible candidates; metformin or berberine considered within provider review.

Reviewed by Dr. Laura PurdyMay 29, 2026

Full answer

Insulin resistance is read from fasting insulin, HOMA-IR, A1C, triglyceride-to-HDL ratio, and ApoB. Lifestyle intervention — resistance training, protein-forward intake, sleep — remains foundational. Provider review evaluates GLP-1 pathways (semaglutide or tirzepatide) for BMI-eligible candidates with insulin resistance or related comorbidities. Metformin and berberine may be discussed within provider review depending on candidacy and tolerability. NAD+ is not a primary insulin-resistance pathway. Every initiation requires the standardized biomarker panel and synchronous video review with recalibration at 8–12 weeks.

Educational. Not a substitute for individualized provider review.

References & sources
  • Glp1 Semaglutide pathway — Primary source · oMeds
  • Reviewed by Dr. Laura Purdy, MD, MBA · Clinical Director, oMeds · Last reviewed 2026-05-29

Related pathways

All pathways →
Pathway
Lipo-B
A lipotropic pathway designed to support metabolic continuity, body composition context, and methylation — reviewed against your biomarkers, not assumed by symptoms.
Explore

Related answers

Insulin resistance explained
Insulin resistance develops when cells respond less to insulin, forcing the pancreas to produce more to keep glucose normal. It precedes type 2 diabetes by years to decades.
What causes insulin resistance?
Insulin resistance is driven by a converging set of factors: excess visceral adiposity, chronic caloric surplus, low muscle mass, poor sleep, chronic inflammation, genetic predisposition, and certain medications. It develops over years and is reversible early in its course.
Does semaglutide improve insulin resistance?
Yes. Semaglutide improves insulin sensitivity through two reinforcing mechanisms: direct GLP-1 receptor effects on insulin and glucagon secretion, and indirect improvement from substantial weight loss. Fasting insulin, HOMA-IR, and A1c all measurably improve in most candidates.
Primary source
Glp1 Semaglutide pathway